Joel Jiang

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

F. Stephen Hodi, Vanna Chiarion‐Sileni, René González et al. · The Lancet Oncology · 2018 · 1.4K citations

Life Sciences, Immunology, Oncology +16

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Neurology, Oncology +14

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Jeffrey S. Weber, F. Stephen Hodi, Jedd D. Wolchok et al. · Journal of Clinical Oncology · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +17

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi, Jason Chesney, Anna C. Pavlick et al. · The Lancet Oncology · 2016 · 980 citations

Medicine, Immunology, Oncology +17

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman et al. · Journal of Clinical Oncology · 2017 · 643 citations · Full text

Medicine, Immunology, Oncology +17